Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in abnormal uterine bleeding

Ayesha Fatima; Syeda Ayesha Siddiqua

doi:10.18203/2320-6012.ijrms20241895

Authors

Ayesha Fatima Department of Obstetrics & Gynecology, National Board of Examinations, Gurgaon Road, New Delhi, India https://orcid.org/0009-0003-5626-673X
Syeda Ayesha Siddiqua Department of Pharmacology, Shadan Institute of Medical Sciences, Teaching Hospital and Research Center, Hyderabad, Telangana, India https://orcid.org/0000-0002-9557-7958

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241895

Keywords:

Abnormal uterine bleeding, Norethisterone, Ormeloxifene

Abstract

Background: Abnormal uterine bleeding is a typical condition for women of reproductive age. It can be painful and uncomfortable, create social disgrace, and have a considerable impact on health-related quality of life. Several studies have shown that ormeloxifene and norethisterone are useful in the treatment of abnormal uterine bleeding, however there is a scarcity of data comparing the efficacy and safety of these medicines.

Methods: A prospective comparative study was conducted over 100 women, age group of 30-50 years, attending the gynecology outpatient department with subjective complaints of heavy menstrual bleeding at a tertiary care hospital, in Hyderabad. Group A (n=50) received 60 mg of ormeloxifene and Group B (n=50) received 5mg of norethisterone, respectively. Ethical approval was taken from the institutional ethical committee.

Results: 38% aged 41-45, 86% had irregular cycles, 76% reported subjective improvement in group A, and 38% in group B. Group A showed a mean difference of 80.22 in decreasing PBAC score, 0.70 in hemoglobin rise, and 3.5 in decreasing ET, while group B showed 53.70 in PBAC decrease, 0.28 in hemoglobin rise, and 1.76 in endometrial thickness reduction. Both groups have no notable side effects and no significant p value.

Conclusions: Reducing PBAC score, subjective improvement, hemoglobin, and endometrial thickness with ormeloxifene and norethisterone works. Ormeloxifene has a far greater effect than norethisterone and has fewer adverse effects.

Metrics

Metrics Loading ...

References

Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in United States. Obstet Gynecol. 2002;100(4):683-7.

Millar WJ. Hysterectomy, 1981/82 to 1996/97. Health Rep. 2001;12(2):9-22.

Sharma A, Dogra Y. Trends of AUB in tertiary centre of Shimla hills. J Midlife Health.213;4(1):67

Hoffman BL, Schorge JO, Schaffer JI, Halvorson M, Bradshaw KD, Gray F (Eds): Abnormal uterine bleeding In: Schorge JD editor. Williams Gynaecology. 2nd ed. New York: McGraw-Hill; 2003:219.

Butler WJ. Normal and abnormal uterine bleeding. In: Rock JA, Thompson JD (eds). Te Linde’s Operative Gynaecology. 8th ed. Philadelphia, Lipincott-Raven; 1997:453-457.

Bravender T Emans SJ. Mentural disorders. Dysfunctional uterine bleeding . Pediatr. Clin North Am. 1999;46(3):545-53.

Spence JE. Anovulation and monophasic cycles. Ann N Y Acad Sci. 1997;16:173-6.

Dhakne PV, Gupta AS. Comparitive study to evaluate efficacy of 30 mg Ormeloxifene to 60 mg of Ormeloxifene in cases of dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2016;5(12):4428-33.

Studd J. Progress in obstetrics and gynecology. In: Current minimal access techniques for dysfunctional uterine bleeding. Churchill Living Stone; 2003:259-272.

Rodriguez MB, Lethaby A, Low C, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochr Datab Systemat Revi. 2019(8).

Vilos GA, Lefebvre G, Graves GR. Guidelines for the management of abnormal uterine bleeding. J Obstet Gynaecol Can. 2001;23(8):704-9.

Shelly W, Draper MW, Krishnana V, Wong M, Jaffe RB. Selective estrogen receptor modulators; an update on recent clinical findings. Obstet Gynecol Surv. 2008;63(3):163-81.

Chhatrala JJ, Chawada R, Saini HB. Comparitive study between Ormeloxifene and oral contraceptive pills in the treatment of dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2015;4(2):366-9.

Lal J. “Clinical pharmackinetics and interaction of Centchroman- a mini review”. Contraception. 2010;81(4):275-80.

Lal J, Nitynand S, Asthana OP, Nagaraja NV, Gupta RC. “The optimization of the contraceptive dosage regimen of centchroman”. Contraception. 2001;63(1):47-51.

Biswas SC, Kumar SS. Ormeloxifene a selective estrogen receptor modulator for treatment of dysfunctional menorrhagia J Obstet Gynecol Ind. 20004;54 (1):56-9.

Gandotra N, Sharma P, Sharma A, Rizvi SM. The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol. 2017;6(1):219-22.

Mandal D, Parmanik S, Surana S, Hazra A, Mandal S, Maity TK. Comparative study of low-dose oral contraceptive pill and ormeloxifene in the treatment of dysfunctional uterine bleeding. Int J Health Allied Sci. 2014;3(4):225-31.

Cardoso PM. A comparative study of the efficacy of ormeloxifene and norethisterone in perimenopausal dysfunctional uterine bleeding and perimenopausal symptoms. IOSR-JDMS. 2016;15(1):2279-0853.

Agarwal N, Singh S, Singh S, Agarwal M, Manocha P. Comparative evaluation ofthe efficacy and safety of ormeloxifene andnorethisterone in dysfunctional uterine bleeding. IntJ Reprod Contracept Obstet Gynecol. 2013;2(2):194-8.

Jacob KJ, Mini, Deepak AV. A comparative study on the effectiveness of ormeloxifene versus norethisterone in the management of perimenopausal dysfunctional uterine bleeding. IAIM. 2015;2(7):87-92.

Sa Karmakar S, Deshpande H. Ormeloxifene. A new treatment modality in Dysfunctional Uterine Bleeding: efficacy and safety. Ind J Obstet Gynecol Res. 2016;3(3):225-8.

Ravibabu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7(11):2534.